John M Maris

John M Maris's AcademicInfluence.com Rankings

John M Maris

Engineering

#3549

World Rank

#4648

Historical Rank

Biomedical Engineering

#175

World Rank

#180

Historical Rank

Applied Physics

#677

World Rank

#699

Historical Rank

engineering Degrees

Download Badge

Engineering

Why Is John M Maris Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John M Maris's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Recent advances in neuroblastoma. (2010) (1569)
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. (2010) (1385)
Identification of ALK as a major familial neuroblastoma predisposition gene (2008) (1285)
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia (1999) (1053)
The genetic landscape of high-risk neuroblastoma (2013) (938)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. (2015) (865)
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. (2013) (617)
Comprehensive Analysis of Hypermutation in Human Cancer (2017) (540)
Pan-cancer genome and transcriptome analyses of 1,699 pediatric leukemias and solid tumors (2018) (506)
Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1 (2000) (503)
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. (2005) (483)
Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia (2004) (472)
The pediatric preclinical testing program: Description of models and early testing results (2007) (434)
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations (2015) (410)
Control of oxidative metabolism and oxygen delivery in human skeletal muscle: a steady-state analysis of the work/energy cost transfer function. (1985) (372)
Molecular biology of neuroblastoma. (1999) (372)
Copy number variation at 1q21.1 associated with neuroblastoma (2009) (364)
Chemoreduction in the initial management of intraocular retinoblastoma. (1996) (337)
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. (2008) (330)
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee (2009) (330)
Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms (2008) (327)
Malignant pheochromocytoma: current status and initiatives for future progress. (2004) (320)
A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene (2008) (318)
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma (2013) (308)
Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study (2017) (302)
Chromosome 1p and 11q deletions and outcome in neuroblastoma. (2005) (299)
ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. (2012) (297)
Children's Oncology Group's 2013 blueprint for research: Neuroblastoma (2013) (290)
Integrative genomics identifies LMO1 as a neuroblastoma oncogene (2011) (280)
Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. (2008) (280)
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma (2009) (268)
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors (2019) (264)
A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. (1995) (260)
Germline PHOX2B mutation in hereditary neuroblastoma. (2004) (249)
Multiple controls of oxidative metabolism in living tissues as studied by phosphorus magnetic resonance. (1986) (249)
Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism (2015) (241)
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma (2011) (241)
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas (1999) (239)
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. (2010) (239)
Biology and genetics of human neuroblastomas. (1997) (236)
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution (2020) (234)
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma (2012) (232)
Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP) (2010) (227)
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma (2011) (223)
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. (2013) (221)
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. (2010) (213)
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. (2007) (213)
MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. (2015) (213)
The biologic basis for neuroblastoma heterogeneity and risk stratification (2005) (199)
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. (2006) (193)
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. (2006) (190)
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. (2017) (179)
CHD5, a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas (2008) (177)
The H+-Linked Monocarboxylate Transporter (MCT1/SLC16A1): A Potential Therapeutic Target for High-Risk Neuroblastoma (2006) (173)
Significance of chromosome 1p loss of heterozygosity in neuroblastoma. (1995) (172)
Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma (2005) (170)
High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma (2008) (166)
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. (2017) (165)
Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations (2016) (165)
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program (2008) (165)
Drosophila Rheb GTPase is required for cell cycle progression and cell growth (2003) (163)
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program (2008) (163)
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. (2010) (163)
Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group (2013) (161)
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. (2019) (160)
Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci (2011) (159)
Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. (2000) (158)
Inhibition of ALK Signaling for Cancer Therapy (2009) (157)
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. (2006) (155)
Prevalence and functional consequence of PHOX2B mutations in neuroblastoma (2008) (152)
Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. (2010) (144)
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project (2012) (141)
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. (2005) (140)
A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants: A Children's Oncology Group Study (2012) (137)
Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. (2005) (134)
Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. (2011) (134)
CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. (2015) (132)
Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. (2005) (131)
Assessment of programmed death‐ligand 1 expression and tumor‐associated immune cells in pediatric cancer tissues (2017) (129)
High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. (2006) (128)
Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program (2008) (128)
Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions. (2006) (125)
Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification (2008) (125)
Genome-Wide Analysis of Neuroblastomas using High-Density Single Nucleotide Polymorphism Arrays (2007) (125)
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. (2017) (124)
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program (2008) (121)
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program (2008) (120)
Molecular Characterization of the Pediatric Preclinical Testing Panel (2008) (116)
Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study (2012) (112)
Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. (2009) (110)
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma (2020) (110)
Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program (2014) (110)
Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. (2013) (110)
Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression (2007) (105)
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study (2015) (105)
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. (2016) (102)
Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. (2013) (100)
Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program (2010) (100)
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. (2004) (99)
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer (2011) (98)
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome (2016) (97)
31P nuclear magnetic resonance spectroscopy: noninvasive biochemical analysis of the ischemic extremity. (1986) (96)
Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. (2012) (96)
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program (2008) (94)
Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing program (2010) (94)
Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines (2017) (94)
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study (2011) (94)
Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program (2010) (93)
Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. (2018) (92)
CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression (2011) (92)
Rare variants in TP53 and susceptibility to neuroblastoma. (2014) (92)
Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. (2002) (92)
High‐resolution detection and mapping of genomic DNA alterations in neuroblastoma (2005) (92)
Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. (2009) (91)
Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature (2010) (90)
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. (2012) (89)
The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. (2001) (89)
Imaging genomics in cancer research: limitations and promises. (2016) (87)
Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy. (2008) (83)
Evaluation of semi‐quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma (2006) (83)
Tumor response and toxicity with multiple infusions of high dose 131I‐MIBG for refractory neuroblastoma (2005) (81)
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group (2021) (81)
A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis. (2015) (81)
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program (2013) (81)
Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). (2006) (81)
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design (2019) (80)
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program (2012) (80)
Common genetic variants in NEFL influence gene expression and neuroblastoma risk. (2014) (79)
11q deletion in neuroblastoma: a review of biological and clinical implications (2017) (78)
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. (2009) (77)
Initial testing of dasatinib by the pediatric preclinical testing program (2008) (76)
Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity. (1998) (74)
Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma (2018) (73)
Initial testing of the replication competent Seneca Valley virus (NTX‐010) by the pediatric preclinical testing program (2010) (73)
Comprehensive analysis of chromosome 1p deletions in neuroblastoma. (2001) (72)
Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. (2017) (71)
New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome (2012) (71)
Physical mapping and genomic structure of the human TNFR2 gene. (1996) (70)
Genetic susceptibility to neuroblastoma. (2017) (69)
Clinical utility of custom-designed NGS panel testing in pediatric tumors (2019) (69)
LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. (2017) (69)
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium (2013) (69)
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673 (2015) (69)
Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma (2010) (68)
Initial testing (stage 1) of the IGF‐1 receptor inhibitor BMS‐754807 by the pediatric preclinical testing program (2011) (68)
Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG (2009) (68)
Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1 (1997) (68)
Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. (2006) (67)
131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. (2015) (67)
Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial (2012) (66)
A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study. (2016) (65)
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations (2020) (65)
Dose Escalation Study of No-Carrier-Added 131I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial (2012) (65)
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma (2012) (64)
Loss of heterozygosity for chromosome 14q in neuroblastoma. (2001) (64)
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients (2018) (64)
Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. (2001) (64)
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma (2016) (63)
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 (2018) (63)
Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. (2003) (62)
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group (2013) (62)
Detailed molecular analysis of 1p36 in neuroblastoma. (2001) (62)
Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity (2020) (62)
Targeted Radiotherapy With Submyeloablative Doses of 131I-MIBG Is Effective for Disease Palliation in Highly Refractory Neuroblastoma (2003) (61)
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. (2020) (61)
Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. (2003) (60)
Testing of new agents in childhood cancer preclinical models: meeting summary. (2002) (60)
Effect of sleep stage on breathing in children with central hypoventilation. (2008) (59)
A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors (2006) (59)
Replication of Neuroblastoma SNP Association at the BARD1 Locus in African-Americans (2012) (57)
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program (2009) (57)
Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program (2013) (56)
A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma (2012) (56)
Initial testing (stage 1) of the multi‐targeted kinase inhibitor sorafenib by the pediatric preclinical testing program (2010) (55)
Focus on embryonal malignancies. (2002) (54)
Thyroid and hepatic function after high‐dose 131I‐metaiodobenzylguanidine (131I‐MIBG) therapy for neuroblastoma (2011) (53)
Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. (2001) (53)
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 (2021) (53)
Molecular genetic analysis of familial neuroblastoma. (1997) (52)
A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High‐Risk Neuroblastoma (2016) (52)
Combination testing (Stage 2) of the Anti‐IGF‐1 receptor antibody IMC‐A12 with rapamycin by the pediatric preclinical testing program (2012) (51)
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs (2021) (51)
Familial predisposition to neuroblastoma does not map to chromosome band 1p36. (1996) (51)
Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization (1997) (50)
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma (2018) (50)
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models (2018) (49)
Initial testing (stage 1) of the polo‐like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program (2014) (48)
Prospects for therapeutic inhibition of neuroblastoma angiogenesis. (2005) (47)
Optimal False Discovery Rate Control for Dependent Data. (2011) (47)
Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. (1997) (46)
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. (2014) (46)
Outcome of high‐risk stage 3 neuroblastoma with myeloablative therapy and 13‐cis‐retinoic acid: A report from the Children's Oncology Group (2009) (46)
Biological aspects of neuroblastomas identified by mass screening in Quebec. (2001) (45)
Initial testing of topotecan by the pediatric preclinical testing program (2010) (45)
Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. (2016) (45)
ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures. (2019) (45)
Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program (2010) (44)
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group (2017) (44)
ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry (2019) (43)
Safety and efficacy of tandem 131I‐metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma (2011) (43)
Rare copy number variants in over 100,000 European ancestry subjects reveal multiple disease associations (2020) (43)
A hidden Markov random field model for genome-wide association studies. (2010) (43)
Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19 (2019) (43)
CXCR4 expression heterogeneity in neuroblastoma cells due to ligand-independent regulation (2009) (42)
Familial neuroblastoma: a three-generation pedigree and a further association with Hirschsprung disease. (1997) (42)
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program (2012) (42)
No CDKN2 mutations in neuroblastomas. (1995) (41)
Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group (2012) (41)
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program (2009) (41)
Prominent Microvascular Proliferation in Clinically Aggressive Neuroblastoma (2007) (40)
CGHAnalyzer: a stand-alone software package for cancer genome analysis using array-based DNA copy number data (2005) (39)
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ‐26481585), by the Pediatric Preclinical Testing Program (2014) (39)
A Pilot Study of Tandem High Dose Chemotherapy with Stem Cell Rescue as Consolidation for High Risk Neuroblastoma: Children’s Oncology Group study ANBL00P1 (2012) (39)
Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. (2000) (39)
Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition (2019) (38)
Proton versus photon radiation therapy for patients with high‐risk neuroblastoma: The need for a customized approach (2013) (38)
Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. (2010) (38)
Testing of the Akt/PKB inhibitor MK‐2206 by the pediatric preclinical testing program (2012) (38)
Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status (2008) (38)
An integrated transcript map of human chromosome 1p35-p36. (1997) (38)
Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma (2020) (37)
The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models (2021) (37)
The challenge of defining “ultra‐high‐risk” neuroblastoma (2018) (37)
Initial testing of the hypoxia‐activated prodrug PR‐104 by the pediatric preclinical testing program (2011) (37)
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program (2012) (37)
Molecular analysis of the region of distal 1p commonly deleted in neuroblastoma. (1997) (37)
Fine mapping of 2q35 high‐risk neuroblastoma locus reveals independent functional risk variants and suggests full‐length BARD1 as tumor‐suppressor (2018) (37)
Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. (2012) (36)
YAP1 mediates resistance to MEK1/2 inhibition in neuroblastomas with hyperactivated RAS signalling. (2019) (36)
Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma (2014) (35)
Biodistribution of post‐therapeutic versus diagnostic 131I‐MIBG scans in children with neuroblastoma (2004) (35)
Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index in Neuroblastoma: A Report from the Children's Oncology Group (2014) (34)
Methionine Aminopeptidase 2 Inhibition Is an Effective Treatment Strategy for Neuroblastoma in Preclinical Models (2005) (34)
Pediatric horner syndrome. (2011) (34)
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ‐secretase inhibitor targeting notch signaling (2012) (34)
Does MYCN Amplification Manifested as Homogeneously Staining Regions at Diagnosis Predict a Worse Outcome in Children with Neuroblastoma? A Children's Oncology Group Study (2006) (34)
Initial testing of the CENP‐E inhibitor GSK923295A by the pediatric preclinical testing program (2012) (34)
AACR Cancer Progress Report 2012 (2012) (33)
MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. (2016) (33)
A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors (2008) (33)
Initial testing of the investigational NEDD8‐activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program (2012) (33)
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. (2021) (33)
Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program (2009) (33)
ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. (2003) (33)
Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. (2019) (33)
Genome-Wide Linkage Analysis to Identify Genetic Modifiers of ALK Mutation Penetrance in Familial Neuroblastoma (2011) (33)
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program (2012) (32)
Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells (2014) (32)
Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17‐DMAG, KOS‐1022) by the pediatric preclinical testing program (2008) (31)
Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma. (2003) (31)
Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. (2000) (31)
High throughput pMHC-I tetramer library production using chaperone-mediated peptide exchange (2019) (31)
Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin‐bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP) (2015) (30)
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial (2017) (30)
Pilot study of intravenous melphalan combined with continuous infusion L‐S,R‐buthionine sulfoximine for children with recurrent neuroblastoma (2015) (29)
The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-β signaling by inactivating the TGF-β type II receptor (2005) (29)
Initial testing of cisplatin by the pediatric preclinical testing program (2008) (29)
Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency (2022) (29)
Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): A Children's Oncology Group (COG A3973) study (2007) (28)
Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. (2019) (28)
Anticancer effects of the novel 1α, 25‐dihydroxyvitamin D3 hybrid analog QW1624F2‐2 in human neuroblastoma (2006) (28)
Human Krüppel-related 3 (HKR3): a candidate for the 1p36 neuroblastoma tumour suppressor gene? (1997) (28)
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT‐330): A report from the pediatric preclinical testing program (2016) (28)
A 6-gene signature identifies four molecular subgroups of neuroblastoma (2011) (28)
MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group (2017) (27)
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. (2020) (27)
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma (2016) (27)
Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism (2015) (27)
Peripheral neuroblastic tumors with genotype–phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee (2013) (27)
MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children’s oncology group (2017) (26)
Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312) (2019) (26)
Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. (2009) (25)
Initial Testing (Stage 1) of MK‐8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program (2016) (25)
Detection of Single-Copy Chromosome 17q Gain in Human Neuroblastomas Using Real-Time Quantitative Polymerase Chain Reaction (2003) (25)
Initial testing (Stage 1) of the antibody‐maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program (2013) (25)
Acetate supplementation restores chromatin accessibility and promotes tumor cell differentiation under hypoxia (2020) (23)
Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era. (2005) (23)
Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models (2019) (23)
Initial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program (2012) (23)
Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk (2017) (23)
BIN1 inhibits colony formation and induces apoptosis in neuroblastoma cell lines with MYCN amplification. (2000) (23)
Differences in Genomic Profiles and Outcomes between Thoracic and Adrenal Neuroblastoma. (2019) (23)
Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma (2016) (23)
Initial testing (stage 1) of SGI‐1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program (2012) (23)
Clinical outcome in children with recurrent neuroblastoma treated with ABT‐751 and effect of ABT‐751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro (2010) (23)
Immunotherapy for pediatric brain tumors: past and present. (2019) (23)
Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. (2017) (22)
MITI minimum information guidelines for highly multiplexed tissue images (2021) (22)
Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma (2011) (22)
Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform. (2005) (22)
Epigenomic profiling of neuroblastoma cell lines (2019) (22)
Cloning, chromosomal localization, physical mapping, and genomic characterization of HKR3. (1996) (22)
Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. (2000) (22)
Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. (2000) (22)
Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes (2016) (22)
Erratum: Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy (Genome Research (2009) 19 (276-283)) (2009) (21)
PARP-1–Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma (2019) (21)
A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations (2018) (21)
Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high‐risk neuroblastoma: A case series (2018) (21)
Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program (2014) (21)
Screening for neuroblastoma: a resurrected idea? (2008) (21)
Unholy matrimony: Aurora A and N-Myc as malignant partners in neuroblastoma. (2009) (19)
Initial testing of VS‐4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program (2017) (19)
Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program (2011) (19)
MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation (2017) (19)
Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program (2013) (19)
Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study. (2020) (18)
Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors (2009) (18)
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT‐751: A report from the Children's Oncology Group (ANBL0621) (2014) (18)
A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children’s Oncology Group study (2008) (18)
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program (2012) (18)
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. (2016) (18)
PI3King on MYCN to improve neuroblastoma therapeutics. (2012) (17)
Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma (2019) (17)
Testing of the topoisomerase 1 inhibitor Genz‐644282 by the pediatric preclinical testing program (2012) (17)
Cancer Therapy : Clinical Phase I Study of Vincristine , Irinotecan , and 131 I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma : A New Approaches to Neuroblastoma Therapy Trial (2012) (17)
Revisiting tissue specificity of germline cancer predisposing mutations (2015) (17)
The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptor. (2005) (17)
Immunogenicity and Immune Silence in Human Cancer (2020) (16)
Analysis of genomic imprinting at 1p35-36 in neuroblastoma. (2001) (16)
Targeting MYCN: a good BET for improving neuroblastoma therapy? (2013) (16)
Initial testing (stage 1) of mapatumumab (HGS‐ETR1) by the pediatric preclinical testing program (2009) (16)
Cortical processing of respiratory occlusion stimuli in children with central hypoventilation syndrome. (2008) (16)
Epigenetic state determines inflammatory sensing in neuroblastoma (2021) (16)
Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children’s Oncology Group (COG) phase II study (2008) (15)
Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma (2020) (15)
Mitogen‐activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere‐associated protein E inhibition (2013) (15)
A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's Oncology Group study. (2014) (15)
LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase (2020) (15)
Initial testing (stage 1) of the anti‐microtubule agents cabazitaxel and docetaxel, by the Pediatric Preclinical Testing Program (2015) (15)
Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program (2017) (15)
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy (2017) (14)
Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma. (2019) (14)
Phase I study of fenretinide (4-HPR) oral powder in patients with recurrent or resistant neuroblastoma: New Approaches to Neuroblastoma Therapy (NANT) Consortium trial. (2009) (14)
Advances in Brief Activating Mutations of the Noonan Syndrome-Associated SHP 2 / PTPN 11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia (2004) (14)
Evidence for genetic homogeneity in a familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML) (1998) (14)
QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction (2018) (14)
Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers (2021) (13)
PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level (2019) (13)
Identification of CASZ1 nuclear export signal (NES) reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma (2016) (12)
Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: A report from the Children’s Oncology Group (COG). (2016) (12)
A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors. (2017) (12)
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program (2013) (12)
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium (2021) (12)
GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma (2021) (11)
Inhibition of ALK mutated neuroblastomas by the selective inhibitor PF-02341066. (2009) (11)
Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy. (2011) (11)
Hepatic absorbed radiation dosimetry during I-131 Metaiodobenzylguanadine (MIBG) therapy for refractory neuroblastoma (2008) (11)
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program (2013) (11)
Mutations in the RAS/MAPK pathway drive replication repair deficient hypermutated tumors and confer sensitivity to MEK inhibition. (2021) (11)
A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children’s Oncology Group study. (2015) (11)
Chromosome arm 11q deletion predicts for neuroblastoma outcome: A Children’s Oncology Group study (2005) (11)
Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report (2020) (11)
Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study (2019) (11)
Physical mapping of the CA6, ENO1, and SLC2A5 (GLUT5) genes and reassignment of SLC2A5 to 1p36.2 (1998) (10)
Initial testing of aplidin by the pediatric pre‐clinical testing program (2009) (10)
Treatment of neuroblastoma in congenital central hypoventilation syndrome with a PHOX2B polyalanine repeat expansion mutation: New twist on a neurocristopathy syndrome (2015) (10)
In vivo phosphorus nuclear magnetic resonance (31P-NMR) study of dystrophic hamster muscle (1988) (10)
ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours (2013) (10)
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. (2021) (10)
Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart Disease (2019) (10)
Rare MYC-amplified Neuroblastoma With Large Cell Histology (2018) (10)
PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma. (2021) (10)
A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope (2021) (9)
Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program (2014) (9)
Homozygous Deletion of CDKN 2 A ( p 16 INK 4 a / p 14 ARF ) but not within 1 p 36 or at Other Tumor Suppressor Loci in Neuroblastoma 1 (2001) (9)
Improving Patient Outcomes With Cancer Genomics: Unique Opportunities and Challenges in Pediatric Oncology. (2015) (9)
Integrating Cell-Based and Clinical Genome-Wide Studies to Identify Genetic Variants Contributing to Treatment Failure in Neuroblastoma Patients (2014) (9)
Mitochondrial DNA haplogroups and susceptibility to neuroblastoma. (2020) (8)
Abstract 4758: Inhibition of checkpoint kinase 1 (Chk1) as a potential therapeutic for pediatric neuroblastoma (2011) (8)
No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3. (2002) (8)
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program (2015) (8)
Abstract LB-353: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib. (2013) (8)
Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB). (2010) (8)
Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma (2003) (7)
Phase I trial and pharmacokinetic (PK) study of ABT-751, an orally bioavailable tubulin binding agent, in pediatric patients with refractory solid tumors. (2004) (7)
Tatton‐Brown‐Rahman syndrome: Six individuals with novel features (2020) (7)
A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children's Oncology Group Phase I Consortium study. (2010) (7)
A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Children’s Oncology Group (2016) (7)
558 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the fully human anti-IGF-1R antibody IMC-A12 (2008) (7)
Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target (2021) (7)
CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma (2020) (7)
Immune-Based Approaches for the Treatment of Pediatric Malignancies (2020) (6)
When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors. (2019) (6)
Initial testing of the replication competent Seneca Valley virus (NTX‐010) by the pediatric preclinical testing program (2012) (6)
Abstract 249: Assessment of PD-L1 expression and tumor-associated lymphocytes in pediatric cancer tissues (2015) (6)
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 (2018) (6)
286 POSTER Pediatric Preclinical Testing Program (PPTP) stage 2 testing of the Aurora A kinase inhibitor MLN8237 (2008) (6)
G-CSF Is a Cancer Stem Cell-Specific Growth Factor-Letter. (2015) (6)
Phosphorus 31 nuclear magnetic resonance spectroscopy of stimulated muscle during starvation (1985) (6)
Initial testing (stage 1) of the notch inhibitor PF‐03084014, by the pediatric preclinical testing program (2014) (6)
Reply to N.-K.V. Cheung et al. (2014) (5)
Conclusions and Future Considerations (2003) (5)
Defining Why Cancer Develops in Children. (2015) (5)
Abstract 4756: Exome sequencing of 81 neuroblastomas identifies a wide diversity of somatic mutation (2011) (5)
Loss of detectable antibody to hepatitis B surface antigen in immunized patients with hemophilia but without human immunodeficiency virus infection. (1995) (5)
Initial testing (Stage 1) of TAK‐701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program (2014) (5)
Familial Neuroblastoma: Report of a Kindred With Later Age at Diagnosis (1998) (5)
Assessment of PD-L1 expression and tumor associated immune cells in pediatric cancer tissues. (2016) (5)
Correction: Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma (2017) (5)
Initial testing of lenalidomide by the pediatric preclinical testing program (2011) (5)
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors (2021) (5)
Neuroblastoma in relation to joint effects of vitamin A and maternal and offspring variants in vitamin A-related genes: A report of the Children's Oncology Group. (2019) (5)
Abstract LB-136: Pediatric Preclinical Testing Consortium evaluation of a DLL3-targeted antibody drug conjugate rovalpituzumab tesirine, in neuroblastoma (2018) (5)
Phase I trial of oral ABT-751 in pediatric patients: Preliminary evidence of activity in neuroblastoma (NBL) (2005) (5)
Abstract CT144: Pediatric phase I trial of the WEE1 inhibitor AZD1775 and irinotecan in patients with refractory solid and CNS malignancies; A Children’s Oncology Group Study (ADVL1312) (2017) (4)
DNMT3A Overgrowth Syndrome is associated with the development of hematopoietic malignancies in children and young adults. (2021) (4)
Abstract C206: Pediatric Preclinical Testing Program (PPTP) evaluation of BMN 673, an inhibitor of Poly-ADP Ribose Polymerase (PARP), alone and with Temozolomide (TMZ). (2013) (4)
How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers (2005) (4)
Clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction (2016) (4)
Are certain children more likely to develop neuroblastoma? (1997) (4)
Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study. (2011) (4)
EFFECTS OF GRADED HYPOXIA ON CEREBRAL PHOSPHATE POTENTIAL IN NEWBORN LAMBS: A CRITICAL BIOENERGETIC LEVEL (1984) (4)
Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib (2007) (4)
Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma. (2022) (4)
COMBINATION THERAPY TARGETING THE CHK1 AND WEE1 KINASES DEMONSTRATES THERAPEUTIC EFFICACY IN NEUROBLASTOMA (2012) (4)
GENT-31. PEDcBIOPORTAL: A CANCER DATA VISUALIZATION TOOL FOR INTEGRATIVE PEDIATRIC CANCER ANALYSES (2016) (4)
Abstract LB-317: Pediatric Preclinical Testing Program (PPTP) evaluation of volasertib (BI 6727), a Polo-like kinase (PLK) inhibitor (2012) (4)
Corrigendum: Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines (2017) (4)
A novel human processed gene, DAD‐R, maps to 12p12 and is expressed in several organs (2000) (4)
Pediatric Preclinical Testing Program (PPTP) evaluation of the multi-targeted kinase inhibitor Sunitinib (2007) (4)
Abstract 2744: CDK4/CDK6 inhibition is potently active in a definable subset of human neuroblastomas. (2013) (4)
31P NHR: QUANTITATION OF MUSCLE EXERCISE PERFORMANCE (1985) (3)
Measurements of muscle metabolism and high energy phosphates in arterial occlusive disease using phosphorus 31 nmr (1984) (3)
Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase (2009) (3)
Abstract 2953: Rev-erbα modulates Myc-driven cancer cell growth and altered metabolism (2014) (3)
Abstract 5566: Elevated CXCR4 expression is clinically correlated with advanced stage neuroblastoma: examination of its role as a possible therapeutic target (2012) (3)
Abstract 2755: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of NSC750854, a sulfamated purine analog with a distinctive anticancer activity profile. (2013) (3)
Cancer Therapy : Preclinical Dual CDK 4 / CDK 6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma (2013) (3)
A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma (2021) (3)
Impact of KIR/KIR ligand genotype for neuroblastoma patients in a phase III COG immunotherapy trial. (2016) (3)
313 POSTER Pediatric preclinical testing program (PPTP) evaluation of the KSP inhibitor Ispinesib (SB-715992) (2006) (3)
hla-Bw 4-i-80 isoform Differentially influences clinical Outcome as compared to hla-Bw 4T-80 and hla-aBw 4 isoforms in rituximab or Dinutuximab-Based cancer immunotherapy (2019) (3)
Pediatric preclinical testing program (PPTP) evaluation of the fully human anti-IGF-1R antibody SCH 717454 (2007) (3)
Chemotherapy for neuroblastoma: is it all or none? (2003) (3)
Genome wide DNA methylation analysis identifies novel molecular subgroups and predicts survival in neuroblastoma (2022) (3)
therapeutic target for high-risk neuroblastoma (2006) (3)
Phase II trial of irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblastoma (NBL): A report from the Children's Oncology Group (COG). (2018) (3)
Initial testing of the histone deacetylase inhibitor Vorinostat by the Pediatric Preclinical Testing Program (2007) (3)
Prognostic markers for stage 3 neuroblastoma (NB): A report from the International Neuroblastoma Risk Group (INRG) project (2008) (3)
MIBG) for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Trial (2012) (2)
Abstract 5237: The long intergenic noncoding RNA LINC00340 is a neuroblastoma susceptibility gene (2014) (2)
Abstract 4881: Dissecting telomere maintenance mechanisms in neuroblastoma (2017) (2)
Abstract 742: Mechanisms of resistance to small molecule inhibition of anaplastic lymphoma kinase in human neuroblastoma (2011) (2)
Abstract 2488: FGFR4 as a potential therapeutic target for monoclonal antibody based intervention in rhabdomyosarcoma (2015) (2)
Identifying Rare Events in Rare Diseases (2014) (2)
Dexmedetomidine does not interfere with meta‐iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations (2017) (2)
1721 THE EFFECT OF SEIZURES ON CEREBRAL METABOUTES IN CHILDREN (1985) (2)
Use of a genome-wide linkage screen to identify a hereditary neuroblastoma predisposition locus at chromosome 2p24–23 (2008) (2)
MEKing Retinoids Work Better (2010) (2)
No CDKN 2 Mutations in Neuroblastomas 1 (2006) (2)
190 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of rapamycin combined with cytotoxic drugs used frequently in treatment of childhood cancer (2008) (2)
Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. (2016) (2)
345 Pediatric Preclinical Testing Program (PPTP) Stage 1 Evaluation of Eribulin (2012) (2)
The pharmacokinetics (PK) and pharmacodynamics (PD) of ABT-751 in children with recurrent neuroblastoma or other solid tumors (2007) (2)
Abstract 3143: Alternative splicing of CD19 mRNA in leukemias escaping CART-19 immunotherapy eliminates the cognate epitope and contributes to treatment failure (2015) (2)
Mutation and Microsatellite Burden Predict Response to PD-1 Inhibition in Children with Germline DNA Replication Repair Deficiency (2021) (2)
Pediatric preclinical testing program (PPTP) efficacy and pharmacodynamic evaluation of the Hsp90 inhibitor 17-DMAG (2007) (2)
Stage 4S Neuroblastoma (2020) (2)
Genetics of neuroblastoma (2001) (2)
Pediatric Preclinical Testing Program (PPTP) evaluation of the mTOR inhibitor rapamycin (2007) (2)
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma (2022) (2)
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma (2022) (1)
Abstract LB-B15: Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan (2018) (1)
Abstract LB-B04: A multi-omic surfaceome study identifies DLK1 as an epigenetically regulated protein and immunotherapeutic target in neuroblastoma (2019) (1)
Abstract PO-049: SARS-CoV-2 multiepitope vaccine constructs designed to drive long-term immunity in the majority of the population (2020) (1)
Identification of genes implicated in angiogenesis using an automated text mining process (2006) (1)
Abstract 1744: RNAseq identified immune signatures associated with adverse outcome in high-risk neuroblastoma (2017) (1)
Author Correction: Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma (2021) (1)
Irinotecan plus temozolomide in children with recurrent or refractory neuroblastoma: A phase II Children's Oncology Group study. (2009) (1)
Abstract 3969: Pediatric preclinical testing program (PPTP) evaluation of BMN 673, an inhibitor of poly-adp ribose polymerase (PARP), with temozolomide (TMZ) (2014) (1)
102 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the VEGFR-2 Inhibitor AZD2171 (2006) (1)
P. Meera Khan (1998) (1)
IMMU-16. TARGETING GLYPICAN 2 (GPC2) ON PEDIATRIC MALIGNANT BRAIN TUMORS WITH MRNA CAR T CELLS (2021) (1)
Abstract 1610: Development of meta-[211At]astatobenzylguanidine ([211At]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma (2015) (1)
Abstract LB-354: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of the XPO1/CRM1 inhibitor KPT-330. (2013) (1)
aberrations across multiple array-CGH experiments STAC : A method for testing the significance of DNA copy number data (2006) (1)
Abstract 5824: MHC class I immunogenicity and novel tumor antigen discovery in neuroblastoma (2017) (1)
HACE1 blocks HIF1α accumulation under hypoxia in a RAC1 dependent manner (2021) (1)
Abstract 2754: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of the antimicrotubule agents cabazitaxel and docetaxel. (2013) (1)
The D3-GPC2-PBD ADC is Potently Efficacious Against Neuroblastoma and SCLC Via Engagement of a Conformational GPC2 Epitope (2020) (1)
and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study (2015) (1)
Abstract LB-318: Pediatric Preclinical Testing Program (PPTP) evaluation of the JAK inhibitor AZD1480 (2012) (1)
O25: Analysis of the genetic similarity of 10 cancer types using genome copy number data (2005) (1)
Abstract 1436: Therapeutic targeting of the DNA damage mediators CHK1 and Wee1 in neuroblastoma (2012) (1)
Abstract 688: Meta-[211At]astatobenzylguanidine ([211At]MABG) is a potent alpha particle emitting systemic targeted radiotherapeutic in preclinical models of neuroblastoma (2017) (1)
Abstract 2786: Establishing validated pediatric cancer cell lines and direct xenografts from post-mortem samples. (2013) (1)
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group (2022) (1)
Abstract CT029: Pediatric phase 2 trial of the WEE1 inhibitor adavosertib (AZD1775) and irinotecan: A Children's Oncology Group Study (ADVL1312) (2021) (1)
Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib (2018) (1)
TB-16EXPLORATION OF eEF2K AS A NOVEL THERAPEUTIC TARGET IN MEDULLOBLASTOMA AND NEUROBLASTOMA (2016) (1)
The microRNA miR-34a is a candidate 1p36 tumor suppressor gene in neuroblastoma (2007) (1)
Abstract B36: Inhibition of Exportin 1 (XPO1) potently suppresses growth of human neuroblastoma cell lines (2014) (1)
Abstract A28: Clinical next-generation sequencing (NGS) reveals genomic alterations (GAs) to guide targeted therapy in advanced neuroblastoma patients (2014) (1)
Abstract 5197: Targeting PARP-1 to deliver alpha-particles to cancer chromatin (2017) (1)
Abstract 5265: Pediatric preclinical testing program (PPTP) stage 1 evaluation of BMS-754807 IGF-1 receptor inhibitor (2010) (1)
Abstract C003: Initial testing of m276-PBD CD276 antibody-drug conjugate in preclinical models of pediatric cancers by the Pediatric Preclinical Testing Consortium (PPTC) (2019) (1)
Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC). (2021) (1)
TM-06MYC AND MYCN DISRUPTION OF THE MOLECULAR CLOCK IN CANCER CELLS (2014) (1)
PDTM-02. STRESS GRANULES ARE INDUCED BY OXIDATIVE STRESS IN PEDIATRIC BRAIN TUMORS AND PREDICT POOR OUTCOME (2018) (1)
Abstract 4636: The antibody-drug conjugate D3-GPC2-PBD potently eradicates neuroblastoma patient-derived xenografts (2018) (1)
Abstract 5358: Pediatric preclinical testing program (PPTP) evaluation of the non-camptothecin topoisomerase 1 targeted agent Genz644282 (2011) (1)
annoFuse: an R Package to annotate, prioritize, and interactively explore putative oncogenic RNA fusions (2020) (1)
THE RELATIONSHIP BETWEEN 3 1-P NMR AND ATHLETIC PERFORMANCE (1986) (1)
Abstract 2425: Genome-wide mapping of MYCN, MYC, and MAX binding across neuroblastoma cell lines identifies novel transcriptional targets (2016) (1)
899 A Three-gene Expression Signature Model for Risk Stratification of Patients With Neuroblastoma (2012) (1)
A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity (2020) (1)
Abstract 1712: CAMKV as an immunotherapy target in MYCN-amplified neuroblastoma (2015) (1)
Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine. (2011) (1)
BIOLOGY AND GENETICS IN HUMAN NEUROBLASTOMA IN NORTH AMERICA (1997) (1)
Abstract 1617: Analysis of single mouse tumor response results from the Pediatric Preclinical Testing Program (PPTP) (2015) (1)
Clinical utility of custom-designed NGS panel testing in pediatric tumors (2019) (1)
LIN28B-PDZ Binding Kinase Signaling Promotes Neuroblastoma Metastasis (2019) (1)
Abstract 2007: Transcriptional regulatory program controlled by the oncogenic transcription factor LMO1 in neuroblastoma (2016) (1)
GENE-05. ATRX IN-FRAME FUSION NEUROBLASTOMA IS SENSITIVE TO EZH2 INHIBITION VIA MODULATION OF NEURONAL GENE SIGNATURES (2019) (1)
1374 CARBON MONOXIDE EFFECT ON BRAIN OXIDATIVE METABOLISM IN NEWBORN PIGLETS (1985) (1)
410 Pediatric Preclinical Testing Program (PPTP) Evaluation of the p53-MDM2 Antagonist MK-8242 (2014) (1)
Abstract A09: Glypican-2 targeted CAR T cells designed to effectively eradicate endogenous site density solid tumors in the absence of toxicity (2020) (1)
Abstract 926: Whole genome and transcriptome sequencing defines the spectrum of somatic changes in high-risk neuroblastoma (2011) (1)
Clinical significance of serial tumor next generation sequencing (NGS) in 155 pediatric cancer patients. (2020) (1)
Abstract 3867: Understanding the neuroblastoma predisposition signal at chromosome 2q35: Identification of the β-BARD1 isoform as an oncogenic driver (2010) (1)
Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias. (2011) (1)
Identification of genomic DNA signatures predicting relapse in low- and intermediate-risk neuroblastoma using a case control design and high-density SNP genotyping: A Children's Oncology Group (COG) study (2007) (1)
Abstract 652: Development and characterization of anti-FGFR4 monoclonal antibodies as therapeutic agents for human rhabdomyosarcoma (2014) (1)
annoFuse: an R Package to annotate, prioritize, and interactively explore putative oncogenic RNA fusions (2019) (1)
Abstract PO-041: Multiplexed ion beam imaging to describe tumor-immune microenvironment and tumor heterogeneity in neuroblastoma (2020) (1)
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. (2023) (1)
Abstract 3494: Combined MEK1/2 and PI3K inhibition induces synergistic caspase-dependent apoptosis in neuroblastoma (2015) (1)
Abstract 3798: Acetate supplementation eliminates hypoxia mediated resistance to differentiation therapy in neuroblastoma cells (2019) (1)
1556 CEREBRAL BIOENERGETIC RESERVE AND BLOOD FLOW COMPENSATION IN HYPOXIC NEWBORN LAMBS (1985) (1)
PARP-1 Targeted Alpha-emitting Radiotherapeutics: An Examination of Potential Toxicity (2019) (1)
SAT-163 Status at 10 Years: Long-Term Follow-Up for a Phase 2a Study of High-Specific-Activity (HSA) I 131 Iobenguane in Patients (Pts) with Relapsed/Refractory High-Risk Neuroblastoma (2020) (1)
Paraneoplastic myasthenia gravis and pemphigus associated with follicular dendritic cell sarcoma leading to cardiorespiratory collapse in a 7‐year‐old (2022) (1)
ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours (2013) (1)
Relationship of divergent ancestral genetic variation on chromosome 6p22 and racial disparities in survival in neuroblastoma. (2012) (0)
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma (2020) (0)
IMMU-04. DEVELOPMENT OF GPC2-DIRECTED CHIMERIC ANTIGEN RECEPTOR THERAPY FOR PEDIATRIC BRAIN TUMORS WITH IN VITRO TRANSCRIBED mRNA (2019) (0)
Abstract B24: Characterization of somatically acquired regulatory mutations in high-risk neuroblastoma (2018) (0)
Abstract B40: MYCN/MYC protein expression in high-MKI (Mitosis-Karyorrhexis Index) neuroblastomas: A report from the Children's Oncology Group (2014) (0)
HLA-A*24:02 bound to Neuroblastoma derived PHOX2B peptide (2021) (0)
Use of 31P NMR in diagnosis and evaluation of therapy of a familial cardiomyopathy (1984) (0)
Abstract 5249: Identification of genome-wide alternative splicing events in high-riskMYCNamplified neuroblastomas (2010) (0)
Targeted inhibition of the centromere-associated protein E (CENP-E) with GSK923295A is effective in preclinical models of human neuroblastoma. (2008) (0)
Abstract 3004: Comparison of somatic alterations in the genome and transcriptome of 1,705 pediatric leukemia and solid tumors: a report from the Children’s Oncology Group (COG) - NCI TARGET Project (2017) (0)
Bresler Found in Neuroblastoma Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants (2011) (0)
Abstract 3816: DNA variation at BARD1 predicts response to aurora kinase inhibition in neuroblastoma. (2013) (0)
Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children’s Oncology Group (COG) risk stratification. (2022) (0)
Page 1 PARP-1-targeted Auger emitters display high-LET cytotoxic properties in vitro but show limited therapeutic utility in solid tumor models of human neuroblastoma Authors (2019) (0)
Molecular Pathways Inhibition of ALK Signaling for Cancer Therapy (2009) (0)
Mitochondrial malfunction in dystrophic hamsters demonstrated by phosphorus 31 nmr (1986) (0)
Abstract B02: Distinct CD8+ T-cell recognition profiles driven by conformational plasticity of recurrent neuroblastoma neoepitopes (2018) (0)
Abstract 5263: An RNAi screen of the protein kinome identifiesCHEK1as a therapeutic target in neuroblastoma (2010) (0)
Abstract 2486: African ancestry is associated with high-risk disease and event-free survival in children with neuroblastoma (2012) (0)
Abstract IA04: Neuroblastoma as a paradigm of MYC(N) driven cancers (2015) (0)
Title: CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors (2018) (0)
Abstract 3030: Heritability of cancer predisposition gene mutations in 556 neuroblastoma patients with paired parental DNA whole genome sequences (2021) (0)
Functional genomic analysis of neuroblastoma for high resolution mapping of 11q deletions (2003) (0)
Phase I trial of lestaurtinib for children with refractory neuroblastoma (NB): A New Approach to Neuroblastoma Therapy (NANT) Consortium study. (2010) (0)
Abstract 3028: Integrative genomics reveals lncRNAs associated with pediatric cancer (2021) (0)
Dosimetry, toxicity, and response in a phase IIa trial of no-carrier added iobenguane I-131 (nca-MIBG): A New Approach to Neuroblastoma Therapy (NANT) study. (2011) (0)
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification. (2023) (0)
Abstract 3000: Defining the subclonal landscape of high-risk neuroblastoma (2017) (0)
Epigenetic regulator BMI1 promotes fusion-positive rhabdomyosarcoma proliferation and constitutes a novel therapeutic target (2020) (0)
Abstract PR10: Oncogenic dysregulations in neuroblastoma are associated with distal large chromosomal aberrations (2015) (0)
Abstract #5676: siRNA screen of the protein kinome identifies therapeutic targets in neuroblastoma (2009) (0)
Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602 (2018) (0)
Abstract 3650: Integrative mass spectrometry and RNA-sequencing identifies DLK1 as a candidate immunotherapeutic target in neuroblastoma (2019) (0)
Abstract B82: MEK 1/2 inhibition and biomarkers of response in preclinical models of neuroblastoma (2014) (0)
Abstract 3512: Dielectrophoretic capture and genetic analysis of individual disseminated solid tumor cells. (2013) (0)
Abstract 484: Fidelity of subclonal representation in human neuroblastoma-derived cell line and patient-derived xenograft models: A report from the NCI-TARGET project (2015) (0)
Abstract 3105: Serial profiling of ctDNA identifies clinically actionable genomic evolution in high-risk neuroblastoma (2019) (0)
Abstract 2625: Patient derived organoids to guide personalized neuroblastoma treatment (2018) (0)
The promises and pitfalls of genetic epidemiologic approaches to pediatric cancers: Lessons from MDM2 (2014) (0)
Letters to the Editor No " Bias " toward the Null Hypothesis in Most Conventional Multipoint Nonparametric Linkage Analyses Comparison of Linkage Statistics Analyses Using All 200 Families and Using Only the 147 Informative Families (2004) (0)
Abstract B48: Preclinical development of meta-[211At] astatobenzylguanidine ([211At] MABG) targeted radiotherapy for neuroblastoma (2014) (0)
Abstract 6051: Longitudinal single-cell sequencing of high-risk neuroblastoma tumors reveals intrinsic and extrinsic mechanisms of therapy resistance (2022) (0)
Faculty Opinions recommendation of Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. (2011) (0)
Does MYCN AmplificationManifested as Homogeneously Staining Regions at Diagnosis Predict aWorse Outcome in Childrenwith Neuroblastoma ? AChildren ’ s Oncology Group Study (2006) (0)
Refining immunotherapeutic approaches to high‐risk neuroblastoma based on tumor genomic profiles (2020) (0)
PDTM-46. TARGETING METABOLIC ADAPTATION IN MYC DRIVEN PEDIATRIC NEURONAL TUMORS (2017) (0)
Principles of Initial Therapy (2003) (0)
Abstract A009: Proteogenomic prioritization of immunotherapeutic targets in rhabdomyosarcoma nominate MEGF10 for preclinical development (2022) (0)
Abstract 475: Identification of SHANK2 as a tumor suppressor disrupted by recurrent somatic structural variation (SV) in neuroblastoma (2015) (0)
Abstract 3218: Transcriptome characterization by RNA sequencing identifies molecular and clinical subgroups in high risk neuroblastoma (2015) (0)
Abstract LB188: Identification of intrinsic molecular vulnerabilities in inherited and treatment-related hypermutant patient-derived glioma cell line models (2022) (0)
A phase II study of 131I-MIBG for refractory neuroblastoma (2005) (0)
Evaluation of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, KOS-1022) against Childhood Cancer Models by the Pediatric Preclinical Testing Program (PPTP) (2006) (0)
A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Children’s Oncology Group (2016) (0)
Diagnosis and Evaluation (2003) (0)
Abstract 4871: New neuroblastoma susceptibility loci at 6q21 withinHACE1andLIN28B (2012) (0)
Abstract 4384: Selective cross-cohort discovery of transcriptional mechanisms presiding over high-risk neuroblastoma subtype state maintenance (2016) (0)
Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency (2022) (0)
Abstract 4685: Mechanistic guidance of ALK inhibition for the treatment of neuroblastoma (2011) (0)
Distal chromosome 6q deletion defines a group of ultra-high risk neuroblastoma patients (2016) (0)
Abstract 5253: Rare copy number variations (CNVs) influence neuroblastoma susceptibility (2010) (0)
Abstract 2593: A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma (2023) (0)
Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children’s Oncology Group (COG) ANBL0032. (2020) (0)
Abstract 690: Identifying the genetic basis of stage 4S neuroblastoma (2017) (0)
Abstract 1616: Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the Pediatric Preclinical Testing Program (2015) (0)
#501 Localization of a neuroblastoma (NB) tumor suppressor gene (TSG) locus within chromosome bands 11q13-23 (1997) (0)
Abstract LB-126: The identification of synthetic lethal partners cooperating with MEK1/2 inhibition in neuroblastoma (2016) (0)
Epigenomic profiling of neuroblastoma cell lines (2020) (0)
#419 Analysis of BIN1, a putative MYCN-interacting tumor suppressor, in neuroblastoma (1999) (0)
Abstract 2886: The Hippo pathway protein YAP mediates resistance to MEK1/2 inhibition in neuroblastoma (2019) (0)
A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1. (2019) (0)
Tumor and Stem Cell Biology Combinatorial Regulation of Neuroblastoma Tumor Progression by N-Myc and Hypoxia Inducible Factor HIF-1a (2010) (0)
Abstract 3811: Rare variants at 16p11.2 and withinTP53influence neuroblastoma susceptibility. (2013) (0)
Genetic analysis in African American children supports ancestry specific neuroblastoma susceptibility. (2022) (0)
Abstract 3889: Identification of ADRN-specific, MES-specific, and pan-subtype therapeutic targets in neuroblastoma (2022) (0)
Advances in Brief No CDKN 2 Mutations in Neuroblastomas 1 (2006) (0)
Abstract 5823: Modulation of the Hippo pathway protein YAP as a mechanism of resistance to MEK inhibition in MAPK hyperactivated neuroblastoma (2017) (0)
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma. (2023) (0)
Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk (2017) (0)
The ASPHO 2014 Distinguished Career Award Goes to Dr. Beverly Lange (2014) (0)
Abstract 5081: Systematic identification of germline mutations in rhabdomyosarcoma and neuroblastoma using massively paralleled sequencing (2014) (0)
Pharmacokinetics (PK) of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. (2012) (0)
PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level (2019) (0)
Giulio J. D'Angio, MD, 1922-2018. (2018) (0)
Molecular Therapy for Neuroblastoma (2010) (0)
#418 TNP-470 inhibits the growth rate and tumorigenicity of human neuroblastoma xenografts (1999) (0)
Abstract SY25-03: Host and tumor genetic architecture influence clinically relevant oncogenic pathways in neuroblastoma (2012) (0)
Study of ABT-751 , an Orally BioavailableTubulin Inhibitor , Administered Daily for 21 Days Every 28 Days in Pediatric Patients with SolidTumors (2008) (0)
Molecular Oncology: Molecular oncology of neuroblastoma (2013) (0)
Clinical Studies Genotypes of NK Cell KIR Receptors , Their Ligands , and Fc g Receptors in the Response of Neuroblastoma Patients to Hu 14 . 18-IL 2 Immunotherapy (2010) (0)
Ultratrace meta-211At-astatobenzylguanidine (211At-MABG) for targeted radiotherapy of neuroendocrine cancer (2014) (0)
BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma (2023) (0)
Author Correction: Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma (2021) (0)
Abstract 3866: Identification ofNME7as a predisposition locus and candidate oncogene in neuroblastoma (2010) (0)
Abstract 685: GPC2 is an oncogene and immunotherapeutic target in high-risk neuroblastoma (2017) (0)
Abstract 2758: Pediatric preclinical testing program (PPTP) stage 1 evaluation of MLN0128, a potent TOR kinase inhibitor. (2013) (0)
Preclinical development of Meta-[211At]astatobenzylguanidine ([211At]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma (NB). (2015) (0)
Abstract 5257: Preclinical evaluation of lestaurtinib (CEP-701) with the retinoids for neuroblastoma (2010) (0)
412 The Pediatric Preclinical Testing Program (PPTP): Analysis of the first 10 years in vivo testing (2014) (0)
Identification of candidate tumor suppressor genes in meningioma by regional expression profiling (2001) (0)
TMOD-09. HUMAN PLURIPOTENT STEM CELL-BASED MODELS OF NEUROBLASTOMA (2017) (0)
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma. (2023) (0)
Therapeutics , Targets , and Chemical Biology Common Variation at BARD 1 Results in the Expression of an Oncogenic Isoform That In fl uences Neuroblastoma Susceptibility and Oncogenicity (2012) (0)
Abstract 1548: Potent activity of CAR T cells targeting the oncofetal protein GPC2 engineered to recognize low antigen density in neuroblastoma (2021) (0)
Image-Guided Biopsy for Relapsed Neuroblastoma: Focus on Safety, Adequacy for Genetic Sequencing, and Correlation of Tumor Cell Percent With Quantitative Lesion MIBG Uptake (2021) (0)
Abstract LB-475: 3′UTR polymorphisms affect expression and activity of IGF1R, a therapeutic target in pediatric neuroblastoma (2012) (0)
Abstract 2633: Advancing childhood cancer research through young investigator and advocate collaboration (2021) (0)
Crossing Oceans: Preclinical Collaboration to Improve Pediatric Drug Development. (2020) (0)
Pediatric Granular Cell Tumors: Clinicopathologic and Molecular Analysis of Six Cases Including Multicentric, Atypical, Malignant, and Non-Neural Tumors (2020) (0)
Abstract B48: A LIN28B-PDZ kinase axis promotes neuroblastoma metastasis (2020) (0)
Angiogenesis Inhibitor TNP-470 During Bone Marrow Transplant and in Minimal Residual Disease (2003) (0)
A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity. (2020) (0)
ReplicationofNeuroblastomaSNPAssociationattheBARD1 Locus in African-Americans (2012) (0)
Identification of novel, rare markers for poor survival in high-risk neuroblastoma patients by merging and reanalysing existing datasets (2017) (0)
Abstract 4743: Genome-wide gene-centric discovery of disease variants in neuroblastoma (2010) (0)
High throughput pMHC-I tetramer library production using chaperone-mediated peptide exchange (2020) (0)
Abstract 1493: Discovery and CAR T targeting of lineage-restricted neuroblastoma oncoproteins (2021) (0)
Abstract 2006: Preclinical evaluation of dual AURKA (LY3295668) and BCL2 (venetoclax) inhibition in neuroblastoma (NB) (2022) (0)
191 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the oncolytic picornavirus, NTX-010 (SVV-001) (2008) (0)
Outcome analysis of non-high-risk neuroblastoma patients enrolled on Children’s Oncology Group trials P9641 and A3961. (2012) (0)
Diagnosis and Staging (2003) (0)
Faculty Opinions recommendation of The TLX1 oncogene drives aneuploidy in T cell transformation. (2010) (0)
Pediatric preclinical testing program (PPTP) evaluation of the MEK1/2 inhibitor AZD6244 (ARRY-142886) (2008) (0)
International consensus for neuroblastoma molecular diagnostics: Report from the international neuroblastoma risk grouping (INRG) Biology committee (2009) (0)
Emmerdale Episode 8223 (2018) (0)
MBRS-57. TARGETING METABOLIC ADAPTATION IN MYC/MYCN AMPLIFIED PEDIATRIC MEDULLOBLASTOMA AND NEUROBLASTOMA (2018) (0)
Abstract 4734: A LIN28B/RAN/AURKA signaling network promotes neuroblastoma tumorigenesis (2015) (0)
Review of: "Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment" (2021) (0)
Abstract B31: Poly(ADP-ribose) Polymerase 1 as a novel target for alpha-particle therapy in high-risk neuroblastoma (2017) (0)
Pediatric Preclinical Testing Program (PPTP) testing of the CENP-E inhibitor GSK923295A. (2009) (0)
Abstract LB-321: Re-evaluating sample sizes in preclinical testing of patient-derived xenografts (2019) (0)
414 Genomic profiling using a clinical next generation sequencing (NGS) assay reveals genomic alterations to guide targeted therapy in advanced neuroblastoma patients (2014) (0)
Abstract 1275: Identification of cancer-specific synthetic lethal genes as novel therapeutic targets (2020) (0)
Abstract 5356: Pediatric preclinical testing program (PPTP) evaluation of the DNA methylating agent temozolomide (2011) (0)
Abstract 144: CASC15 is a tumor suppressor lncRNA at the 6p22 neuroblastoma susceptibility locus (2015) (0)
Abstract 5258: Genomic characterization and targeted resequencing of high-risk neuroblastoma (the neuroblastoma TARGET) (2010) (0)
Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma (2022) (0)
Abstract 1615: Initial testing (stage 1) of the Curaxin, CBL0137, by the Pediatric Preclinical Testing Program (PPTP) (2015) (0)
Abstract 5266: Pediatric Preclinical Testing Program (PPTP) evaluation of the CDK inhibitor SCH 727965 (2010) (0)
Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis (2022) (0)
Abstract 501: Inhibition of exportin 1 (XPO1) by selinexor (KPT-330) synergistically suppresses growth of neuroblastoma in combination with doxorubicin or bromodomain inhibition (2015) (0)
Abstract B34: Antitumor activity and sensitivity evaluation of novel BET inhibitors in neuroblastoma (2015) (0)
A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma. (2020) (0)
Abstract 3804: Rare DNA variants are enriched at the BARD1 locus and likely influence neuroblastoma susceptibility. (2013) (0)
Sensitivity to a poly(ADP-ribose) Polymerase 1 (PARP-1) Targeting Alpha Particle Therapeutic in Neuroblastoma Is Characterized by Increased Relative Biological Effectiveness (RBE) Compared to Gamma Irradiation (2019) (0)
Genetic Predisposition to Neuroblastoma Results from a Regulatory Polymorphism that Promotes the Adrenergic Cell State (2023) (0)
Abstract 2756: Targeted inhibition of Chromosomal Maintenance Region Protein (CRM1) potently suppresses growth of human neuroblastoma cell line models. (2013) (0)
Abstract PR02: GPC2 is a candidate immunotherapeutic target and putative oncogene in high-risk neuroblastoma and other pediatric cancers (2016) (0)
Advances in Brief Identification of a Consistent Region of Allelic Loss on Ip 32 in Meningiomas : Correlation with Increased Morbidity 1 (2006) (0)
Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Childrens Oncology Group (COG). (2016) (0)
Faculty Opinions recommendation of Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. (2011) (0)
Abstract 126: The transcriptome landscape of high-risk neuroblastoma (2016) (0)
Germline pathogenic variants in 786 neuroblastoma patients (2023) (0)
Abstract LB-127: Loss of function ofGAS7promotes neuroblastoma metastasis in the context ofMYCNoverexpression (2019) (0)
Abstract 3809: The role ofLIN28BandRANin promoting neuroblastoma tumorigenesis. (2013) (0)
A Phase 1Study of ABT-751, an Orally BioavailableTubulin Inhibitor, Administered Daily for 7 Days Every 21Days in Pediatric Patients with Solid Tumors (2006) (0)
Abstract 4305: NMI as a biomarker of response to CDK4/6 inhibition in a preclinical model of neuroblastoma (2015) (0)
Integrative genomics identifies lncRNA regulatory networks across 1,044 pediatric leukemias and extra-cranial solid tumors (2020) (0)
Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408). (2011) (0)
False Discovery Rate Control for High Dimensional Dependent Data with an Application to Large-Scale Genetic Association Studies (2010) (0)
322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825) (2006) (0)
Abstract 3230: Human stem cell-based model of MYCN-driven neuroblastoma (2015) (0)
The Children's Hospital of Philadelphia Research Institute Impact Factor Report, FY2008 (2008) (0)
Abstract 5015: Hcasz5, CASZ1 gene transcript variant 2 with 5 zinc fingers functions as a tumor suppressor in Neuroblastoma (2010) (0)
Abstract A27: A noncoding polymorphism in a GATA-containing enhancer element drives the association of LMO1 with neuroblastoma (2014) (0)
Prominent vascular endothelial proliferation in clinically aggressive neuroblastoma (2007) (0)
Abstract 6714: ALCAM promotes neuroblastoma proliferation, migration, and immune evasion (2023) (0)
Abstract A46: Genomic ancestry is associated with risk group and survival in children with neuroblastoma (2011) (0)
Presentations by TTUHSC SOM Cancer Center at AACR 2010 (2010) (0)
Acetate supplementation restores chromatin accessibility and promotes tumor cell differentiation under hypoxia (2020) (0)
Rare copy number variants in over 100,000 European ancestry subjects reveal multiple disease associations (2020) (0)
131I-MIBG with myeloablative chemotherapy for neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) phase I study (2005) (0)
In memoriam: Dr. Audrey E. Evans. (2022) (0)
Abstract C15: Combinatorial regulation of neuroblastoma tumor progression by HIF1α and N‐myc transcriptional factors (2009) (0)
Abstract #5178: Novel candidate neuroblastoma tumor suppressor genes, APOA1 and XPC, are identified in regions of recurrent copy number aberration following genome-wide methylation profiling. (2009) (0)
Abstract 740: Pediatric Preclinical Testing Program (PPTP) evaluation of the NEDD8-activating enzyme (NAE) inhibitor MLN4924 (2011) (0)
Genomic landscape of 261 childhood cancer patient-derived xenograft models (2019) (0)
Abstract A26: Characterization and development of a GPC2 ADC for neuroblastoma and other cancers (2020) (0)
Dr Audrey E. Evans (1925-2022): academic trailblazer par excellence. (2022) (0)
Abstract 5708: Deciphering Warburg effect: hypoxia inhibits tumor cell differentiation through reducing acetyl-CoA generation and chromatin accessibility (2020) (0)
135 Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of JNJ-26481585, a second generation histone deacetylase inhibitor (2010) (0)
Abstract 3921: Poly(ADP-ribose) polymerase 1 (PARP-1) targeting radionuclides are highly cytotoxic across a panel of 20 neuroblastoma cell lines (2019) (0)
Multiple controls ofoxidative metabolism inliving tissues as studied byphosphorus magnetic resonance (1986) (0)
Abstract LB-225: Expression- and immune-profiling of neuroblastoma associated with Opsoclonus-myoclonus-ataxia syndrome (OMAS) to identify features of auto- and tumor immunity (2017) (0)
Faculty Opinions recommendation of Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. (2009) (0)
Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program (2016) (0)
Abstract 684: Integrative proteomics and transcriptomics to define the cell surface landscape of neuroblastoma (2017) (0)
Abstract 4515: PIONEER: harnessing multi-omics data to enhance immunotherapeutic target discovery and development (2023) (0)
ERRATUM (1962) (0)
Abstract 5256: The identification of fatty acid synthase (FASN) as a candidate oncogene and therapeutic target in neuroblastoma (2010) (0)
Abstract B75: Defining the antitumor activity and sensitivity profiles of BET inhibitors in neuroblastoma (2014) (0)
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group (2023) (0)
The Concept of Risk-Related Therapy (2003) (0)
Abstract 2431: Enrichment of targetable mutations in the relapsed neuroblastoma genome (2016) (0)
Increased 18F-fluoro-L-DOPA (F-DOPA) uptake by neuroblastoma (2006) (0)
HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide (2021) (0)
Imaging , Diagnosis , Prognosis A Three-Gene Expression Signature Model for Risk Strati fi cation of Patients with Neuroblastoma (2012) (0)
Image-guided core needle biopsy for relapsed and refractory neuroblastoma: A focus on sample adequacy for genetic sequencing. (2020) (0)
Abstract #5679: Identification of RAN as a neuroblastoma oncogene (2009) (0)
In Memoriam: Giulio D'Angio, MD, May 2, 1922-September 14, 2018. (2019) (0)
Abstract 356: Role of the LMO1 oncogene in neuroblastoma pathogenesis. (2013) (0)
Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study. (2022) (0)
TBIO-29. PedcBioPortal, A CANCER DATA VISUALIZATION TOOL FOR INTEGRATIVE PEDIATRIC CANCER ANALYSES (2018) (0)
Identification of Mitochondrial DNA Variants Associated With Risk of Neuroblastoma. (2022) (0)
Abstract A37: Immunohistochemical detection of MYCN protein and MYC protein identifies highly aggressive neuroblastomas (2015) (0)
HLA-A*02:01 bound to Neuroblastoma Derived mutant IGFBPL1 peptide (2021) (0)
11q deletion in neuroblastoma: a review of biological and clinical implications (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With John M Maris?

John M Maris is affiliated with the following schools:

University of California, Los Angeles
Vanderbilt University
Stanford University
University of Chicago
University of Washington
University of California, San Francisco
Sapienza University of Rome
University of Pennsylvania
Harvard University
Kangwon National University
Ghent University

John M Maris's Academic­Influence.com Rankings

Why Is John M Maris Influential?

John M Maris's Published Works

Published Works

What Schools Are Affiliated With John M Maris?

John M Maris's AcademicInfluence.com Rankings